Rising Biosciences (Rising Biosciences) Price-to-Tangible-Book : (As of Jun. 17, 2024)

View and export this data going back to . Start your Free Trial

What is Rising Biosciences Price-to-Tangible-Book?

As of today (2024-06-17), Rising Biosciences's share price is $0.0001. Rising Biosciences's Tangible Book per Share of . 20 for the quarter that ended in . 20 was $0.00. Hence, Rising Biosciences's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Rising Biosciences's Price-to-Tangible-Book or its related term are showing as below:

RBII's Price-to-Tangible-Book is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 2.33
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Rising Biosciences's share price is $0.0001. Rising Biosciences's Book Value per Sharefor the quarter that ended in . 20 was $0.00. Hence, Rising Biosciences's P/B Ratio of today is .

Rising Biosciences Price-to-Tangible-Book Historical Data

The historical data trend for Rising Biosciences's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rising Biosciences Price-to-Tangible-Book Chart

Rising Biosciences Annual Data

Trend

Price-to-Tangible-Book

Rising Biosciences Quarterly Data

Price-to-Tangible-Book

Competitive Comparison of Rising Biosciences's Price-to-Tangible-Book

For the Drug Manufacturers - Specialty & Generic subindustry, Rising Biosciences's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rising Biosciences's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rising Biosciences's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Rising Biosciences's Price-to-Tangible-Book falls into.

Rising Biosciences Price-to-Tangible-Book Calculation

Rising Biosciences's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: . 20 )
	=	0.0001	/
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Rising Biosciences Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Rising Biosciences's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Rising Biosciences (Rising Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » Price-to-Tangible-Book

Traded in Other Exchanges

N/A

Address

1180 Cleveland Road, Sandusky, OH, USA, 44870

Website

http://www.risingbiosciences.com

Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.